ATE323720T1 - Zinkfinger-bindungsdomänen für gnn - Google Patents

Zinkfinger-bindungsdomänen für gnn

Info

Publication number
ATE323720T1
ATE323720T1 AT99953825T AT99953825T ATE323720T1 AT E323720 T1 ATE323720 T1 AT E323720T1 AT 99953825 T AT99953825 T AT 99953825T AT 99953825 T AT99953825 T AT 99953825T AT E323720 T1 ATE323720 T1 AT E323720T1
Authority
AT
Austria
Prior art keywords
gnn
zinkfinger
binding domain
polypeptides
compositions
Prior art date
Application number
AT99953825T
Other languages
English (en)
Inventor
Carlos F Barbas
Original Assignee
Novartis Erfind Verwalt Gmbh
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Erfind Verwalt Gmbh, Scripps Research Inst filed Critical Novartis Erfind Verwalt Gmbh
Application granted granted Critical
Publication of ATE323720T1 publication Critical patent/ATE323720T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT99953825T 1998-10-16 1999-10-14 Zinkfinger-bindungsdomänen für gnn ATE323720T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/173,941 US6140081A (en) 1998-10-16 1998-10-16 Zinc finger binding domains for GNN

Publications (1)

Publication Number Publication Date
ATE323720T1 true ATE323720T1 (de) 2006-05-15

Family

ID=22634148

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99953825T ATE323720T1 (de) 1998-10-16 1999-10-14 Zinkfinger-bindungsdomänen für gnn
AT06007722T ATE509101T1 (de) 1998-10-16 1999-10-14 Zinkfinger-bindungsdomänen für gnn

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT06007722T ATE509101T1 (de) 1998-10-16 1999-10-14 Zinkfinger-bindungsdomänen für gnn

Country Status (17)

Country Link
US (5) US6140081A (de)
EP (2) EP1715040B1 (de)
JP (2) JP2002527097A (de)
KR (1) KR100659922B1 (de)
CN (2) CN1269958C (de)
AT (2) ATE323720T1 (de)
AU (1) AU765630B2 (de)
BR (1) BR9914599A (de)
CA (1) CA2347025C (de)
DE (1) DE69930950T2 (de)
DK (1) DK1121381T3 (de)
ES (1) ES2263290T3 (de)
IL (3) IL142440A0 (de)
MX (1) MXPA01003755A (de)
NZ (4) NZ529583A (de)
WO (1) WO2000023464A2 (de)
ZA (1) ZA200102908B (de)

Families Citing this family (476)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7285416B2 (en) * 2000-01-24 2007-10-23 Gendaq Limited Regulated gene expression in plants
GB9824544D0 (en) 1998-11-09 1999-01-06 Medical Res Council Screening system
US7262055B2 (en) 1998-08-25 2007-08-28 Gendaq Limited Regulated gene expression in plants
CA2196419C (en) 1994-08-20 2007-08-21 Yen Choo Improvements in or relating to binding proteins for recognition of dna
US6410248B1 (en) 1998-01-30 2002-06-25 Massachusetts Institute Of Technology General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
DE69942334D1 (de) 1998-03-02 2010-06-17 Massachusetts Inst Technology Poly-zinkfinger-proteine mit verbesserten linkern
DE69932813D1 (de) 1998-03-17 2006-09-28 Gendaq Ltd Nukleinsäurebindungsproteine
US6140081A (en) * 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US6503717B2 (en) 1999-12-06 2003-01-07 Sangamo Biosciences, Inc. Methods of using randomized libraries of zinc finger proteins for the identification of gene function
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7070934B2 (en) 1999-01-12 2006-07-04 Sangamo Biosciences, Inc. Ligand-controlled regulation of endogenous gene expression
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US7013219B2 (en) * 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US20030104526A1 (en) 1999-03-24 2003-06-05 Qiang Liu Position dependent recognition of GNN nucleotide triplets by zinc fingers
US7030215B2 (en) * 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
US7329728B1 (en) 1999-10-25 2008-02-12 The Scripps Research Institute Ligand activated transcriptional regulator proteins
WO2001053480A1 (en) * 2000-01-24 2001-07-26 Sangamo Biosciences, Inc. Nucleic acid binding polypeptides characterized by flexible linkers connected nucleic acid binding modules
AU2001250774B2 (en) 2000-02-08 2005-01-27 Sangamo Biosciences, Inc. Cells expressing zinc finger proteins for drug discovery
US7923542B2 (en) 2000-04-28 2011-04-12 Sangamo Biosciences, Inc. Libraries of regulatory sequences, methods of making and using same
US7217509B2 (en) 2000-04-28 2007-05-15 Sangamo Biosciences, Inc. Databases of regulatory sequences; methods of making and using same
AU2001257421A1 (en) 2000-04-28 2001-11-12 Sangamo Biosciences, Inc. Pharmacogenomics and identification of drug targets by reconstruction of signal transduction pathways based on sequences of accessible regions
AU2001257331A1 (en) 2000-04-28 2001-11-12 Sangamo Biosciences, Inc. Methods for designing exogenous regulatory molecules
EP1276859B1 (de) 2000-04-28 2007-02-07 Sangamo Biosciences Inc. Gezielten modifikation der chromatinstruktur
EP1908835A3 (de) * 2000-07-18 2008-06-18 Novartis AG Regulierung von Genexpression durch einkettige, monomere, ligandenabhängige Polypeptidschalter
US7011972B2 (en) 2000-07-18 2006-03-14 The Scripps Research Institute Fusion polypeptide comprising two ligand binding domains
IL154059A0 (en) * 2000-07-21 2003-07-31 Syngenta Participations Ag Zinc finger domain recognition code and uses thereof
US7067317B2 (en) * 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
WO2002046412A2 (en) * 2000-12-07 2002-06-13 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7273923B2 (en) * 2001-01-22 2007-09-25 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
US7947469B2 (en) * 2001-01-22 2011-05-24 Gendaq, Ltd. Modulation of HIV infection
EP1364027B1 (de) * 2001-02-21 2009-09-02 Novartis AG Die nukleotidsequenz ann bindende zink-finger domänen
US7067617B2 (en) * 2001-02-21 2006-06-27 The Scripps Research Institute Zinc finger binding domains for nucleotide sequence ANN
US20040197892A1 (en) * 2001-04-04 2004-10-07 Michael Moore Composition binding polypeptides
WO2002097050A2 (en) 2001-05-31 2002-12-05 Novartis Ag Novel estrogen receptor ligand binding domain variants and novel ligands and pharmaceutical compositions
US20040224385A1 (en) * 2001-08-20 2004-11-11 Barbas Carlos F Zinc finger binding domains for cnn
US7262054B2 (en) * 2002-01-22 2007-08-28 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
ATE347593T1 (de) * 2002-01-23 2006-12-15 Univ Utah Res Found Zielgerichtete chromosomale mutagenese mit zinkfingernukleasen
AU2003215094B2 (en) * 2002-02-07 2008-05-29 The Scripps Research Institute Zinc finger libraries
EP1504092B2 (de) * 2002-03-21 2014-06-25 Sangamo BioSciences, Inc. Verfahren und zusammensetzungen zur verwendung von zinkfinger-endonukleasen zur verbesserung der homologen rekombination
EP1532178A4 (de) * 2002-06-11 2006-10-25 Scripps Research Inst Synthetische transkriptionsfaktoren
US7361635B2 (en) 2002-08-29 2008-04-22 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes
US9447434B2 (en) * 2002-09-05 2016-09-20 California Institute Of Technology Use of chimeric nucleases to stimulate gene targeting
WO2004046387A1 (en) * 2002-11-15 2004-06-03 Sangamo Biosciences, Inc. Methods and compositions for analysis of regulatory sequences
US8071285B1 (en) 2003-05-14 2011-12-06 Carl Henry Lawyer Zinc finger protein derivatives and methods of using same
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
EP2927318B1 (de) 2003-08-08 2020-05-20 Sangamo Therapeutics, Inc. Verfahren und Zusammensetzungen für gezielte Spaltung und Rekombination
US11311574B2 (en) 2003-08-08 2022-04-26 Sangamo Therapeutics, Inc. Methods and compositions for targeted cleavage and recombination
US20120196370A1 (en) 2010-12-03 2012-08-02 Fyodor Urnov Methods and compositions for targeted genomic deletion
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
CA2539439C (en) 2003-09-19 2012-10-23 Sangamo Biosciences, Inc. Engineered zinc finger proteins for regulation of gene expression
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
AU2005233583B2 (en) * 2004-04-08 2011-02-03 Sangamo Therapeutics, Inc. Methods and compositions for modulating cardiac contractility
ATE418346T1 (de) * 2004-04-08 2009-01-15 Sangamo Biosciences Inc Zusammensetzungen zur behandlung von neuropathischen und neurodegenerativen erkrankungen
US7253273B2 (en) * 2004-04-08 2007-08-07 Sangamo Biosciences, Inc. Treatment of neuropathic pain with zinc finger proteins
KR20070060115A (ko) 2004-09-16 2007-06-12 상가모 바이오사이언스 인코포레이티드 단백질 생산을 위한 조성물 및 방법
EP2163632A1 (de) 2004-10-05 2010-03-17 SunGene GmbH Konstitutive Expressionskassetten zur Regulation der Pflanzenexpression
EP1655364A3 (de) 2004-11-05 2006-08-02 BASF Plant Science GmbH Expressionskassetten zur bevorzugten Expression in Pflanzensamen
EP1662000B1 (de) 2004-11-25 2011-03-30 SunGene GmbH Expressionskassetten zur bevorzugten Expression in pflanzlichen Schliesszellen
EP1666599A3 (de) 2004-12-04 2006-07-12 SunGene GmbH Expressionskassetten zur bevorzugten Expression in Mesophyll- und/oder Epidermiszellen in Pflanzen
EP1669455B1 (de) 2004-12-08 2009-10-28 SunGene GmbH Expressionskassetten für preferentiell vaskuläre Expression in Pflanzen
EP1669456A3 (de) 2004-12-11 2006-07-12 SunGene GmbH Expressionskasseten für meristembevorzugte Expression in Pflanzen
EP2163633A1 (de) 2005-02-09 2010-03-17 BASF Plant Science GmbH Expressionskassetten zur Regulation der Expression in einkeimblättrigen Pflanzen
AU2006217847B2 (en) 2005-02-26 2011-04-07 Basf Plant Science Gmbh Expression cassettes for seed-preferential expression in plants
CA2599004C (en) 2005-02-28 2015-05-26 Sangamo Biosciences, Inc. Anti-angiogenic methods and compositions
AU2006245701B2 (en) 2005-05-10 2011-04-28 Basf Plant Science Gmbh Expression cassettes for seed-preferential expression in plants
EP1913149A4 (de) 2005-07-26 2009-08-05 Sangamo Biosciences Inc Gezielte integration und expression exogener nukleinsäuresequenzen
JP2009504156A (ja) * 2005-08-11 2009-02-05 ザ スクリップス リサーチ インスティテュート Ｃｎｎに対するジンクフィンガー結合ドメイン
WO2007048127A2 (en) * 2005-10-20 2007-04-26 The Scripps Research Institute Fc labeling for immunostaining and immunotargeting
CA2631422A1 (en) * 2005-11-28 2007-05-31 The Scripps Research Institute Zinc finger binding domains for tnn
US20070154989A1 (en) * 2006-01-03 2007-07-05 The Scripps Research Institute Zinc finger domains specifically binding agc
WO2007106603A2 (en) * 2006-01-06 2007-09-20 The Scripps Research Institute Specific labeling of proteins with zinc finger tags and use of zinc-finger-tagged proteins for analysis
WO2007136685A2 (en) * 2006-05-19 2007-11-29 Sangamo Biosciences, Inc. Methods and compositions for inactivation of dihydrofolate reductase
EP2027262B1 (de) * 2006-05-25 2010-03-31 Sangamo Biosciences Inc. Variante foki-spaltungshälften-domänen
US7951925B2 (en) 2006-05-25 2011-05-31 Sangamo Biosciences, Inc. Methods and compositions for gene inactivation
JP2010500029A (ja) 2006-08-11 2010-01-07 ダウ アグロサイエンシィズ エルエルシー ジンクフィンガーヌクレアーゼ媒介相同組換え
WO2008060510A2 (en) 2006-11-13 2008-05-22 Sangamo Biosciences, Inc. Zinc finger nuclease for targeting the human glucocorticoid receptor locus
CA2669746C (en) * 2006-12-14 2017-05-16 Dow Agrosciences Llc Optimized non-canonical zinc finger proteins
KR20090119910A (ko) 2007-02-16 2009-11-20 바스프 플랜트 사이언스 게엠베하 외떡잎 식물에서 배-특이적 발현의 조절을 위한 핵산 서열
US8110379B2 (en) 2007-04-26 2012-02-07 Sangamo Biosciences, Inc. Targeted integration into the PPP1R12C locus
AU2008275649B2 (en) 2007-07-12 2013-09-05 Sangamo Therapeutics, Inc. Methods and compositions for inactivating alpha 1,6 fucosyltransferase (FUT 8) gene expression
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
JP5763341B2 (ja) * 2007-09-27 2015-08-12 サンガモ バイオサイエンシーズ， インコーポレイテッド 生物学的活性のあるヌクレアーゼの迅速なインビボ同定法
ES2585157T3 (es) 2007-09-27 2016-10-04 Dow Agrosciences Llc Proteínas de dedo de cinc de diseño que se dirigen a los genes de 5-enolpiruvil shikimato-3-fosfato sintasa
US11235026B2 (en) 2007-09-27 2022-02-01 Sangamo Therapeutics, Inc. Methods and compositions for modulating PD1
EP2597155B1 (de) 2007-10-25 2016-11-23 Sangamo BioSciences, Inc. Verfahren und Zusammensetzungen für gezielte Integration
CA2704271C (en) 2007-12-03 2016-07-19 Syngenta Participations Ag Engineering enzymatically susceptible phytases
AU2009212247A1 (en) * 2008-02-08 2009-08-13 Sangamo Therapeutics, Inc. Treatment of chronic pain with zinc finger proteins
WO2009130695A2 (en) 2008-04-21 2009-10-29 Danziger Innovation Ltd. Plant viral expression vectors and use of same for generating genotypic variations in plant genomes
PL2274430T3 (pl) 2008-04-30 2017-09-29 Sanbio Inc Komórki regenerujące nerwy ze zmianami w metylacji DNA
CA2725773C (en) * 2008-05-28 2017-12-05 Sangamo Biosciences, Inc. Compositions for linking dna-binding domains and cleavage domains
JP5763530B2 (ja) * 2008-06-10 2015-08-12 サンガモ バイオサイエンシーズ， インコーポレイテッド Ｂａｘ−およびＢａｋ−欠損細胞株の生成のための方法および組成物
JP5908725B2 (ja) 2008-08-22 2016-04-26 サンガモ バイオサイエンシーズ， インコーポレイテッド 標的一本鎖開裂および標的組込みのための方法、並びに組成物
JP5756016B2 (ja) * 2008-10-29 2015-07-29 サンガモ バイオサイエンシーズ， インコーポレイテッド グルタミンシンセターゼ遺伝子の発現を不活性化する方法及び組成物
WO2010056808A2 (en) * 2008-11-12 2010-05-20 The Regents Of The University Of California Compositions and methods for re-programming and re-differentiating cells
US20110023156A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Feline genome editing with zinc finger nucleases
US20110023139A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in cardiovascular disease
US20110023146A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in secretase-associated disorders
US20110023151A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of abc transporters
EP3156494B8 (de) 2008-12-04 2018-09-19 Sangamo Therapeutics, Inc. Genomänderung bei ratten mithilfe von zink-finger-nukleasen
US20110023154A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Silkworm genome editing with zinc finger nucleases
US20110016543A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genomic editing of genes involved in inflammation
US20110023153A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in alzheimer's disease
US20110023141A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved with parkinson's disease
US20110016546A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Porcine genome editing with zinc finger nucleases
US20110016540A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genome editing of genes associated with trinucleotide repeat expansion disorders in animals
US20110023158A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Bovine genome editing with zinc finger nucleases
US20110023150A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of genes associated with schizophrenia in animals
US20110023145A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in autism spectrum disorders
US20110030072A1 (en) * 2008-12-04 2011-02-03 Sigma-Aldrich Co. Genome editing of immunodeficiency genes in animals
US20110023140A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Rabbit genome editing with zinc finger nucleases
US20110023147A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of prion disorder-related genes in animals
US20110016539A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genome editing of neurotransmission-related genes in animals
US20110023149A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in tumor suppression in animals
US20110023144A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in amyotrophyic lateral sclerosis disease
US20110023143A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of neurodevelopmental genes in animals
US20110016541A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genome editing of sensory-related genes in animals
US20110023148A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of addiction-related genes in animals
US20110023152A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of cognition related genes in animals
AU2009333863B2 (en) * 2008-12-17 2015-02-05 Corteva Agriscience Llc Targeted integration into the Zp15 locus
WO2010090744A1 (en) 2009-02-04 2010-08-12 Sangamo Biosciences, Inc. Methods and compositions for treating neuropathies
CA2755192C (en) * 2009-03-20 2018-09-11 Sangamo Biosciences, Inc. Modification of cxcr4 using engineered zinc finger proteins
AU2010235161B2 (en) * 2009-04-09 2015-01-22 Sangamo Therapeutics, Inc. Targeted integration into stem cells
US8772008B2 (en) * 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
EP2449135B1 (de) 2009-06-30 2016-01-06 Sangamo BioSciences, Inc. Schnelles screening biologisch aktiver nukleasen und isolation nukleasemodifizierter zellen
CA2769262C (en) * 2009-07-28 2019-04-30 Sangamo Biosciences, Inc. Methods and compositions for treating trinucleotide repeat disorders
NZ598457A (en) * 2009-08-03 2014-06-27 Recombinetics Inc Methods and compositions for targeted gene modification
CN102612565B (zh) 2009-08-11 2016-04-06 桑格摩生物科学股份有限公司 靶向修饰的纯合生物体
US9476060B2 (en) 2009-10-21 2016-10-25 Danziger Innovations Ltd. Generating genotypic variations in plant genomes by gamete infection
CN102782140B (zh) 2009-10-22 2016-04-13 陶氏农业科学有限公司 靶向参与脂肪酸生物合成的植物基因的工程改造锌指蛋白
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
CN102725412B (zh) 2009-11-27 2017-09-22 巴斯夫植物科学有限公司 优化的内切核酸酶及其用途
CA2787494C (en) 2010-01-22 2019-09-17 Dow Agrosciences Llc Targeted genomic alteration
JP6137596B2 (ja) 2010-02-08 2017-05-31 サンガモ セラピューティクス， インコーポレイテッド 遺伝子操作された切断ハーフドメイン
US9255259B2 (en) 2010-02-09 2016-02-09 Sangamo Biosciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
US9567573B2 (en) 2010-04-26 2017-02-14 Sangamo Biosciences, Inc. Genome editing of a Rosa locus using nucleases
EP2566972B1 (de) 2010-05-03 2020-01-15 Sangamo Therapeutics, Inc. Zusammensetzungen zur verknüpfung von zinkfingermodulen
CA2805442C (en) 2010-07-21 2020-05-12 Sangamo Biosciences, Inc. Methods and compositions for modification of an hla locus
EP3511420B1 (de) 2010-09-27 2021-04-07 Sangamo Therapeutics, Inc. Zusammensetzungen zur hemmung des eindringens von viren in zellen
EP2627665B1 (de) 2010-10-12 2015-12-16 The Children's Hospital Of Philadelphia Verfahren und Zusammensetzungen zur Behandlung von Hämophilie B
WO2012094132A1 (en) 2011-01-05 2012-07-12 Sangamo Biosciences, Inc. Methods and compositions for gene correction
MX2013010197A (es) 2011-03-18 2013-09-26 Basf Plant Science Co Gmbh Promotores para regular la expresion en plantas.
US20140186340A1 (en) 2011-04-08 2014-07-03 Gilead Biologics, Inc. Methods and Compositions for Normalization of Tumor Vasculature by Inhibition of LOXL2
CA2841541C (en) 2011-07-25 2019-11-12 Sangamo Biosciences, Inc. Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (cftr) gene
EP2758529B1 (de) 2011-09-21 2019-03-20 Sangamo Therapeutics, Inc. Verfahren und zusammensetzungen zur regulierung der transgenexpression
US8951752B2 (en) 2011-10-20 2015-02-10 University Of Iowa Research Foundation N-demethyase genes and uses thereof
US9222105B2 (en) 2011-10-27 2015-12-29 Sangamo Biosciences, Inc. Methods and compositions for modification of the HPRT locus
JP6023218B2 (ja) 2012-01-27 2016-11-09 サンバイオ，インコーポレイティド 血管新生及び血管発生を調節するための方法及び組成物
CA2865011C (en) 2012-02-29 2021-06-15 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
DK2839013T3 (da) 2012-04-18 2020-09-14 Univ Leland Stanford Junior Ikke-disruptiv-gen-targetering
EP2841572B1 (de) 2012-04-27 2019-06-19 Duke University Genetische korrektur mutierter gene
AU2013256240B2 (en) 2012-05-02 2018-09-20 Corteva Agriscience Llc Targeted modification of malate dehydrogenase
CA2871524C (en) 2012-05-07 2021-07-27 Sangamo Biosciences, Inc. Methods and compositions for nuclease-mediated targeted integration of transgenes
US11120889B2 (en) 2012-05-09 2021-09-14 Georgia Tech Research Corporation Method for synthesizing a nuclease with reduced off-site cleavage
US20150184166A1 (en) 2012-06-15 2015-07-02 Uinversity of Iowa Research Foundation Caffeine responsive promoters and regulatory genes
HUE051612T2 (hu) 2012-07-11 2021-03-01 Sangamo Therapeutics Inc Eljárások és készítmények lizoszomális tárolási betegségek kezelésére
WO2014011901A2 (en) 2012-07-11 2014-01-16 Sangamo Biosciences, Inc. Methods and compositions for delivery of biologics
US10648001B2 (en) 2012-07-11 2020-05-12 Sangamo Therapeutics, Inc. Method of treating mucopolysaccharidosis type I or II
EP2890780B8 (de) 2012-08-29 2020-08-19 Sangamo Therapeutics, Inc. Verfahren und zusammensetzungen zur behandlung eines genetischen leidens
EP4148134A1 (de) 2012-09-04 2023-03-15 The Scripps Research Institute Chimäre polypeptide mit gerichteter bindungsspezifität
BR112015004995B1 (pt) 2012-09-07 2023-05-02 Sangamo Biosciences, Inc. Método para modificação do genoma de uma célula, uso de uma célula, semente ou planta obtida pelo referido método e nuclease de dedo de zinco sítio específica
UA119135C2 (uk) 2012-09-07 2019-05-10 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Спосіб отримання трансгенної рослини
UA118090C2 (uk) 2012-09-07 2018-11-26 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Спосіб інтегрування послідовності нуклеїнової кислоти, що представляє інтерес, у ген fad2 у клітині сої та специфічний для локусу fad2 білок, що зв'язується, здатний індукувати спрямований розрив
WO2014059173A2 (en) 2012-10-10 2014-04-17 Sangamo Biosciences, Inc. T cell modifying compounds and uses thereof
CA2892448A1 (en) 2012-12-05 2014-06-12 Sangamo Biosciences, Inc. Methods and compositions for regulation of metabolic disorders
CA2895117A1 (en) 2012-12-13 2014-06-19 James W. Bing Precision gene targeting to a particular locus in maize
US10227610B2 (en) 2013-02-25 2019-03-12 Sangamo Therapeutics, Inc. Methods and compositions for enhancing nuclease-mediated gene disruption
US9828582B2 (en) 2013-03-19 2017-11-28 Duke University Compositions and methods for the induction and tuning of gene expression
AU2014235968B2 (en) 2013-03-21 2018-05-24 Ospedale San Raffaele Srl Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
CN105263312A (zh) 2013-04-05 2016-01-20 美国陶氏益农公司 用于在植物基因组内整合外源序列的方法和组合物
US10604771B2 (en) 2013-05-10 2020-03-31 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
WO2014186435A2 (en) 2013-05-14 2014-11-20 University Of Georgia Research Foundation, Inc. Compositions and methods for reducing neointima formation
EP2997146A4 (de) 2013-05-15 2017-04-26 Sangamo BioSciences, Inc. Verfahren und zusammensetzungen zur behandlung eines genetischen leidens
CA2920899C (en) 2013-08-28 2023-02-28 Sangamo Biosciences, Inc. Compositions for linking dna-binding domains and cleavage domains
US10117899B2 (en) 2013-10-17 2018-11-06 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
EP3058072B1 (de) 2013-10-17 2021-05-19 Sangamo Therapeutics, Inc. Freisetzungsverfahren und zusammensetzungen für nukleasevermitteltes genomengineering
EP3066110B1 (de) 2013-11-04 2021-12-29 Corteva Agriscience LLC Optimale maispflanzen
JP6633532B2 (ja) 2013-11-04 2020-01-22 ダウ アグロサイエンシィズ エルエルシー 最適なトウモロコシ遺伝子座
CN105980395A (zh) 2013-11-04 2016-09-28 美国陶氏益农公司 最优大豆座位
WO2015066643A1 (en) 2013-11-04 2015-05-07 Dow Agrosciences Llc Optimal soybean loci
MX391904B (es) 2013-11-11 2025-03-12 Sangamo Biosciences Inc Un represor genetico para usarse en el tratamiento de la enfermedad de huntington.
ES2721936T3 (es) 2013-11-13 2019-08-06 Childrens Medical Center Regulación de la expresión genética mediada por las nucleasas
US9932607B2 (en) 2013-11-15 2018-04-03 The Board Of Trustees Of The Leland Stanford Junior University Site-specific integration of transgenes into human cells
CA3229275A1 (en) 2013-12-09 2015-06-18 Sangamo Biosciences, Inc. Methods and compositions for genome engineering
US10774338B2 (en) 2014-01-16 2020-09-15 The Regents Of The University Of California Generation of heritable chimeric plant traits
PT3102673T (pt) 2014-02-03 2020-05-21 Sangamo Biosciences Inc Métodos e composições para tratamento de beta-talassemia
EP3110454B1 (de) 2014-02-24 2020-11-18 Sangamo Therapeutics, Inc. Verfahren und zusammensetzungen zur nukleasevermittelten gezielten integration
TW201538518A (zh) 2014-02-28 2015-10-16 Dow Agrosciences Llc 藉由嵌合基因調控元件所賦予之根部特異性表現
EP3929279A1 (de) 2014-03-18 2021-12-29 Sangamo Therapeutics, Inc. Verfahren und zusammensetzungen zur regulierung der zinkfingerproteinexpression
US10612041B2 (en) 2014-03-21 2020-04-07 The Board Of Trustees Of The Leland Stanford Junior University Genome editing without nucleases
WO2015153889A2 (en) 2014-04-02 2015-10-08 University Of Florida Research Foundation, Incorporated Materials and methods for the treatment of latent viral infection
US9522936B2 (en) 2014-04-24 2016-12-20 Sangamo Biosciences, Inc. Engineered transcription activator like effector (TALE) proteins
BR112016025849A2 (pt) 2014-05-08 2017-10-17 Chdi Foundation Inc métodos e composições para o tratamento da doença de huntington
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
EP3721875B1 (de) 2014-05-09 2023-11-08 Yale University Mit hyperverzweigtem polyglycerol beschichtete partikel und verfahren zu deren herstellung
WO2015175642A2 (en) 2014-05-13 2015-11-19 Sangamo Biosciences, Inc. Methods and compositions for prevention or treatment of a disease
US9970001B2 (en) 2014-06-05 2018-05-15 Sangamo Therapeutics, Inc. Methods and compositions for nuclease design
US20170159065A1 (en) 2014-07-08 2017-06-08 Vib Vzw Means and methods to increase plant yield
EP3169778B1 (de) 2014-07-14 2023-10-25 Washington State University Nanos-knock-out zur abladierung von keimbahnzellen
US10738278B2 (en) 2014-07-15 2020-08-11 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
US11278572B2 (en) 2014-07-18 2022-03-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Reducing CXCR4 expression and/or function to enhance engraftment of hematopoietic stem cells
WO2016014837A1 (en) 2014-07-25 2016-01-28 Sangamo Biosciences, Inc. Gene editing for hiv gene therapy
WO2016014794A1 (en) 2014-07-25 2016-01-28 Sangamo Biosciences, Inc. Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
US9616090B2 (en) 2014-07-30 2017-04-11 Sangamo Biosciences, Inc. Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
CN113699113A (zh) 2014-09-16 2021-11-26 桑格摩治疗股份有限公司 用于造血干细胞中核酸酶介导的基因组工程化和校正的方法和组合物
US10889834B2 (en) 2014-12-15 2021-01-12 Sangamo Therapeutics, Inc. Methods and compositions for enhancing targeted transgene integration
US20180002379A1 (en) 2015-01-21 2018-01-04 Sangamo Therapeutics, Inc. Methods and compositions for identification of highly specific nucleases
US10626372B1 (en) 2015-01-26 2020-04-21 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
US10676726B2 (en) 2015-02-09 2020-06-09 Duke University Compositions and methods for epigenome editing
JP6964843B2 (ja) * 2015-03-31 2021-11-10 国立研究開発法人農業・食品産業技術総合研究機構 バイナリー遺伝子発現システム
CA2981077A1 (en) 2015-04-03 2016-10-06 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
KR20170136573A (ko) 2015-04-15 2017-12-11 다우 아그로사이언시즈 엘엘씨 트랜스젠 발현을 위한 식물 프로모터
BR112017021903B1 (pt) 2015-04-15 2023-12-05 Corteva Agriscience Llc Promotor de planta para expressão de transgene
EP3292219B9 (de) 2015-05-04 2022-05-18 Ramot at Tel-Aviv University Ltd. Verfahren und kits zur fragmentierung von dna
US10179918B2 (en) 2015-05-07 2019-01-15 Sangamo Therapeutics, Inc. Methods and compositions for increasing transgene activity
SG10202112057QA (en) 2015-05-12 2021-12-30 Sangamo Therapeutics Inc Nuclease-mediated regulation of gene expression
MX2017015239A (es) 2015-05-29 2018-02-19 Juno Therapeutics Inc Composicion y metodos para regular interacciones inhibitorias en celulas geneticamente modificadas.
US9957501B2 (en) 2015-06-18 2018-05-01 Sangamo Therapeutics, Inc. Nuclease-mediated regulation of gene expression
CA2991301A1 (en) 2015-07-13 2017-01-19 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
HRP20240908T1 (hr) 2015-08-06 2024-10-25 The Curators Of The University Of Missouri Svinja i stanice otporne na virus reproduktivnog i respiratornog sindroma svinja (prrsv) koje imaju modificirane cd163 gene
TW201718861A (zh) 2015-09-22 2017-06-01 道禮責任有限公司 用於轉殖基因表現之植物啟動子及３’ｕｔｒ
TW201718862A (zh) 2015-09-22 2017-06-01 Dow Agrosciences Llc 用於轉殖基因表現之植物啟動子及３’ｕｔｒ
DK3352776T3 (da) 2015-09-23 2025-06-23 Sangamo Therapeutics Inc Htt-repressorer og deres anvendelse
WO2017066497A2 (en) 2015-10-13 2017-04-20 Duke University Genome engineering with type i crispr systems in eukaryotic cells
EP3365451B1 (de) 2015-10-22 2020-06-24 Dow Agrosciences LLC Pflanzenpromoter zur transgenen expression
US20170121726A1 (en) 2015-11-04 2017-05-04 Dow Agrosciences Llc Plant promoter for transgene expression
CN122146606A (zh) 2015-11-04 2026-06-05 菲特治疗公司 用于诱导造血细胞分化的方法和组合物
US12642852B1 (en) 2015-11-04 2026-06-02 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
EP3380622A4 (de) 2015-11-23 2019-08-07 Sangamo Therapeutics, Inc. Verfahren und zusammensetzungen zum immunitäts-engineering
US12214054B2 (en) 2015-11-30 2025-02-04 Duke University Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use
US11352631B2 (en) 2015-12-18 2022-06-07 Sangamo Therapeutics, Inc. Targeted disruption of the T cell receptor
AU2016374253B2 (en) 2015-12-18 2021-10-21 Sangamo Therapeutics, Inc. Targeted disruption of the MHC cell receptor
EP3402533B1 (de) 2016-01-15 2021-08-04 Sangamo Therapeutics, Inc. Verfahren und zusammensetzungen zur behandlung von neurologischer erkrankung
JP7012650B2 (ja) 2016-02-02 2022-01-28 サンガモ セラピューティクス， インコーポレイテッド Ｄｎａ結合ドメインと切断ドメインとを連結するための組成物
JP2019508037A (ja) 2016-02-16 2019-03-28 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔ 標的化遺伝子編集を増強するための組成物およびその使用方法
AU2017221424A1 (en) 2016-02-16 2018-09-20 Yale University Compositions and methods for treatment of cystic fibrosis
US11421218B2 (en) 2016-03-23 2022-08-23 Dana-Farber Cancer Institute, Inc. Methods for enhancing the efficiency of gene editing
WO2017173453A1 (en) 2016-04-01 2017-10-05 The Brigham And Women's Hospital, Inc. Stimuli-responsive nanoparticles for biomedical applications
EP3443081A4 (de) 2016-04-13 2019-10-30 Duke University Crispr/cas9-basierte repressoren zur in-vivo-ausschaltung von gen-targets und verfahren zur verwendung
US11410746B2 (en) 2016-04-27 2022-08-09 Massachusetts Institute Of Technology Stable nanoscale nucleic acid assemblies and methods thereof
US11514331B2 (en) 2016-04-27 2022-11-29 Massachusetts Institute Of Technology Sequence-controlled polymer random access memory storage
US20200182884A1 (en) 2016-06-27 2020-06-11 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
JP7054397B2 (ja) 2016-06-27 2022-04-13 ジュノー セラピューティクス インコーポレイテッド Ｍｈｃ－ｅ拘束性エピトープ、結合分子ならびに関連する方法および使用
WO2018013840A1 (en) 2016-07-13 2018-01-18 Vertex Pharmaceuticals Incorporated Methods, compositions and kits for increasing genome editing efficiency
JP7490211B2 (ja) 2016-07-19 2024-05-27 デューク ユニバーシティ Ｃｐｆ１に基づくゲノム編集の治療適用
JP7325104B2 (ja) 2016-07-27 2023-08-14 ケース ウェスタン リザーブ ユニバーシティ ミエリン形成を促進する化合物および方法
WO2018029034A1 (en) 2016-08-09 2018-02-15 Vib Vzw Cellulose synthase inhibitors and mutant plants
IL264792B2 (en) 2016-08-24 2023-10-01 Sangamo Therapeutics Inc Engineered target-specific zinc-finger nucleases
WO2018039440A1 (en) 2016-08-24 2018-03-01 Sangamo Therapeutics, Inc. Regulation of gene expression using engineered nucleases
JP7256739B2 (ja) 2016-09-07 2023-04-12 サンガモ セラピューティクス， インコーポレイテッド 肝臓遺伝子のモジュレーション
KR20190062505A (ko) 2016-10-03 2019-06-05 주노 쎄러퓨티크스 인코퍼레이티드 Hpv-특이적 결합 분자
WO2018067265A1 (en) 2016-10-03 2018-04-12 Dow Agrosciences Llc Plant promoter for transgene expression
CN110291199B (zh) 2016-10-03 2023-12-22 美国陶氏益农公司 用于转基因表达的植物启动子
CA3038690A1 (en) 2016-10-05 2018-04-12 FUJIFILM Cellular Dynamics, Inc. Generating mature lineages from induced pluripotent stem cells with mecp2 disruption
EP3525803B1 (de) 2016-10-13 2022-12-07 Juno Therapeutics, Inc. Immuntherapieverfahren und zusammensetzungen mit tryptophan-stoffwechselweg-modulatoren
KR102712926B1 (ko) 2016-10-20 2024-10-07 상가모 테라퓨틱스, 인코포레이티드 파브리병의 치료를 위한 방법 및 조성물
US11766400B2 (en) 2016-10-24 2023-09-26 Yale University Biodegradable contraceptive implants
WO2018081775A1 (en) 2016-10-31 2018-05-03 Sangamo Therapeutics, Inc. Gene correction of scid-related genes in hematopoietic stem and progenitor cells
CN110214184B (zh) 2016-12-01 2024-07-02 桑格摩生物治疗股份有限公司 τ蛋白调节剂以及用于其递送的方法和组合物
WO2018102612A1 (en) 2016-12-02 2018-06-07 Juno Therapeutics, Inc. Engineered b cells and related compositions and methods
WO2018106732A1 (en) 2016-12-05 2018-06-14 Juno Therapeutics, Inc. Production of engineered cells for adoptive cell therapy
EP4276187A3 (de) 2016-12-08 2024-01-17 Case Western Reserve University Verfahren und zusammensetzungen zur erhöhung der herstellung von funktionalem myelin
WO2018112470A1 (en) 2016-12-16 2018-06-21 The Brigham And Women's Hospital, Inc. Co-delivery of nucleic acids for simultaneous suppression and expression of target genes
AU2018224387B2 (en) 2017-02-22 2024-08-08 Crispr Therapeutics Ag Compositions and methods for gene editing
CN117821509A (zh) 2017-04-03 2024-04-05 编码治疗公司 组织选择性转基因表达
WO2018187493A1 (en) 2017-04-04 2018-10-11 Yale University Compositions and methods for in utero delivery
MX2019010286A (es) 2017-04-20 2019-10-21 Univ Oregon Health & Science Correccion de genes humanos.
US11820728B2 (en) 2017-04-28 2023-11-21 Acuitas Therapeutics, Inc. Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
JP2020518245A (ja) 2017-05-03 2020-06-25 サンガモ セラピューティクス， インコーポレイテッド 嚢胞性線維症膜貫通コンダクタンス制御因子（ｃｆｔｒ）遺伝子の改変のための方法および組成物
ES2875579T3 (es) 2017-06-06 2021-11-10 Zymergen Inc Plataforma de ingeniería genómica de HTP para mejorar Escherichia coli
US11512287B2 (en) 2017-06-16 2022-11-29 Sangamo Therapeutics, Inc. Targeted disruption of T cell and/or HLA receptors
CN111278276B (zh) 2017-06-28 2023-05-26 美国陶氏益农公司 用于转基因表达的植物启动子
JP2020530997A (ja) 2017-08-08 2020-11-05 サンガモ セラピューティクス， インコーポレイテッド キメラ抗原受容体媒介性細胞標的化
US11952408B2 (en) 2017-10-03 2024-04-09 Juno Therapeutics, Inc. HPV-specific binding molecules
WO2019089402A1 (en) 2017-10-30 2019-05-09 Dow Agrosciences Llc Plant promoter for transgene expression
US11851679B2 (en) 2017-11-01 2023-12-26 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
WO2019094725A2 (en) 2017-11-09 2019-05-16 Sangamo Therapeutics, Inc. Genetic modification of cytokine inducible sh2-containing protein (cish) gene
WO2019094928A1 (en) 2017-11-10 2019-05-16 Massachusetts Institute Of Technology Microbial production of pure single stranded nucleic acids
US10953036B2 (en) 2017-11-20 2021-03-23 University Of Georgia Research Foundation, Inc. Compositions and methods of modulating HIF-2A to improve muscle generation and repair
CN118345115A (zh) 2017-12-01 2024-07-16 编码治疗公司 工程化的dna结合蛋白
WO2019125851A1 (en) 2017-12-18 2019-06-27 Syngenta Participations Ag Targeted insertion sites in the maize genome
BR112020011017A2 (pt) 2017-12-22 2020-11-17 Fate Therapeutics, Inc. células efetoras imunes intensificadas e uso das mesmas
US12269804B2 (en) 2018-01-17 2025-04-08 Vertex Pharmaceuticals Incorporated Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency
WO2019143678A1 (en) 2018-01-17 2019-07-25 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
BR112020014140A2 (pt) 2018-01-17 2020-12-01 Vertex Pharmaceuticals Incorporated inibidores de dna-pk
US12509492B2 (en) 2018-01-19 2025-12-30 Duke University Genome engineering with CRISPR-Cas systems in eukaryotes
BR112020015488A2 (pt) 2018-02-08 2020-12-08 Sangamo Therapeutics, Inc. Nucleases alvo-específicas modificadas
AU2019243315A1 (en) 2018-03-29 2020-09-24 Fate Therapeutics, Inc. Engineered immune effector cells and use thereof
CN112585276A (zh) 2018-04-05 2021-03-30 朱诺治疗学股份有限公司 产生表达重组受体的细胞的方法和相关组合物
CN112566698A (zh) 2018-04-05 2021-03-26 朱诺治疗学股份有限公司 T细胞受体和表达该t细胞受体的工程化细胞
CN112585277A (zh) 2018-04-05 2021-03-30 朱诺治疗学股份有限公司 表达重组受体的t细胞、相关多核苷酸和方法
JP7332622B2 (ja) 2018-04-18 2023-08-23 サンガモ セラピューティクス， インコーポレイテッド ハンチンチン（ｈｔｔ）の調節のためのジンクフィンガータンパク質組成物
US20200063100A1 (en) 2018-05-11 2020-02-27 Crispr Therapeutics Ag Methods and compositions for treating cancer
US11690921B2 (en) 2018-05-18 2023-07-04 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
GB201809273D0 (en) 2018-06-06 2018-07-25 Vib Vzw Novel mutant plant cinnamoyl-coa reductase proteins
EP3802839A1 (de) 2018-06-07 2021-04-14 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) Nukleinsäurekonstrukte und verfahren zu deren verwendung
EP3800998A1 (de) 2018-06-07 2021-04-14 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) Verfahren zur regenerierung und transformation von cannabis
US11939593B2 (en) 2018-08-01 2024-03-26 University Of Georgia Research Foundation, Inc. Compositions and methods for improving embryo development
JP7541508B2 (ja) 2018-08-23 2024-08-28 サンガモ セラピューティクス， インコーポレイテッド 操作された標的特異的な塩基エディター
EP3844287B1 (de) 2018-08-31 2024-05-22 Yale University Zusammensetzungen und verfahren zur verbesserung der oligonukleotidbasierten geneditierung
BR112021003823A2 (pt) 2018-08-31 2021-05-25 Yale University composição, composição farmacêutica e método para modificar o genoma de uma célula
EP4234570A3 (de) 2018-09-18 2023-12-13 Sangamo Therapeutics, Inc. Für programmierten zelltod 1 (pd1) spezifische nukleasen
EP3852911B1 (de) 2018-09-21 2025-01-22 Acuitas Therapeutics, Inc. Systeme und verfahren zur herstellung von lipidnanopartikeln und liposomen
IL326834A (en) 2018-10-02 2026-04-01 Sangamo Therapeutics Inc Artificial zinc finger protein transcription factors repressing mapt expression for the prevention and/or treatment of tauopathies
CA3116576A1 (en) 2018-10-18 2020-04-23 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
EA202191257A1 (ru) 2018-11-07 2021-12-06 Криспр Терапьютикс Аг Противораковая терапия на основе иммуноцитов, связывающих liv1
SG11202103832SA (en) 2018-11-07 2021-05-28 Crispr Therapeutics Ag Anti-cd33 immune cell cancer therapy
US12146157B2 (en) 2018-11-07 2024-11-19 Crispr Therapeutics Ag Anti-PTK7 immune cell cancer therapy
WO2020112195A1 (en) 2018-11-30 2020-06-04 Yale University Compositions, technologies and methods of using plerixafor to enhance gene editing
JP2022510207A (ja) 2018-12-02 2022-01-26 フェイト セラピューティクス，インコーポレイテッド 増強されたｉＰＳＣ派生エフェクター細胞を使用した免疫療法
CA3121781A1 (en) 2018-12-05 2020-06-11 Vertex Pharmaceuticals Incorporated Gene-editing systems for editing a cystic fibrosis transmembrane regulator (cftr) gene
GB201820109D0 (en) 2018-12-11 2019-01-23 Vib Vzw Plants with a lignin trait and udp-glycosyltransferase mutation
CN113423419A (zh) 2019-01-04 2021-09-21 桑格摩生物治疗股份有限公司 用于治疗法布里病的方法和组合物
PL3908568T3 (pl) 2019-01-11 2024-12-02 Acuitas Therapeutics, Inc. Lipidy do dostarczania środków czynnych w nanocząstkach lipidowych
US12156877B1 (en) 2019-01-15 2024-12-03 The Regents Of The University Of California Methods of treating conditions related to a thiamine deficiency, a thiamine-dependent enzyme, or an associated cofactor
US12642850B2 (en) 2019-01-24 2026-06-02 Massachusetts Institute Of Technology Nucleic acid nanostructure platform for programming immune stimulation
WO2020154595A1 (en) 2019-01-24 2020-07-30 Massachusetts Institute Of Technology Nucleic acid nanostructure platform for antigen presentation and vaccine formulations formed therefrom
CA3106693A1 (en) 2019-02-06 2020-08-13 Sangamo Therapeutics, Inc. Method for the treatment of mucopolysaccharidosis type i
BR112021017770A2 (pt) 2019-03-08 2021-11-16 Obsidian Therapeutics Inc Composições e métodos de cd40l para regulação ajustável
WO2020205838A1 (en) 2019-04-02 2020-10-08 Sangamo Therapeutics, Inc. Methods for the treatment of beta-thalassemia
TWI887234B (zh) 2019-04-14 2025-06-21 美國公爵大學 治療杜興氏（ｄｕｃｈｅｎｎｅ）肌肉失養症之大型突變熱點之ａａｖ載體介導之刪除
JP7618581B2 (ja) 2019-04-23 2025-01-21 サンガモ セラピューティクス， インコーポレイテッド ９番染色体オープンリーディングフレーム７２遺伝子発現のモジュレーターおよびその使用
SG11202111372VA (en) 2019-05-01 2021-11-29 Juno Therapeutics Inc Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
CA3136737A1 (en) 2019-05-01 2020-11-05 Juno Therapeutics, Inc. Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
SG11202113048SA (en) 2019-05-29 2021-12-30 Encoded Therapeutics Inc Compositions and methods for selective gene regulation
US11905532B2 (en) 2019-06-25 2024-02-20 Massachusetts Institute Of Technology Compositions and methods for molecular memory storage and retrieval
AU2020307667A1 (en) 2019-06-27 2022-01-20 Crispr Therapeutics Ag Use of chimeric antigen receptor T cells and NK cell inhibitors for treating cancer
KR20220035190A (ko) 2019-07-17 2022-03-21 페이트 세러퓨틱스, 인코포레이티드 면역 효과기 세포 조작 및 이의 용도
CA3144413A1 (en) 2019-07-17 2021-01-21 Rafick-Pierre Sekaly Long lived t cells for treating hiv infection
EP4007596A1 (de) 2019-08-01 2022-06-08 Sana Biotechnology, Inc. Dux4+-exprimierende zellen und ihre verwendungen
JP7728747B2 (ja) 2019-08-23 2025-08-25 サナ バイオテクノロジー，インコーポレイテッド Ｃｄ２４発現細胞およびそれらの用途
KR20220101073A (ko) 2019-08-30 2022-07-19 예일 유니버시티 핵산을 세포로 전달하기 위한 조성물 및 방법
PH12022550548A1 (en) 2019-09-06 2023-11-20 Crispr Therapeutics Ag Genetically engineered t cells having improved persistence in culture
US20230002459A1 (en) 2019-10-02 2023-01-05 Sangamo Therapeutics, Inc. Zinc Finger Protein Transcription Factors for Treatment of Prion Disease
TW202132565A (zh) 2019-11-01 2021-09-01 美商聖加莫治療股份有限公司 Ｇｉｎ重組酶變異體
WO2021087366A1 (en) 2019-11-01 2021-05-06 Sangamo Therapeutics, Inc. Compositions and methods for genome engineering
AU2021205416B2 (en) 2020-01-08 2026-08-06 Obsidian Therapeutics, Inc. Compositions and methods for tunable regulation of transcription
CA3166153A1 (en) 2020-01-28 2021-08-05 The Broad Institute, Inc. Base editors, compositions, and methods for modifying the mitochondrial genome
EP4125961A1 (de) 2020-03-25 2023-02-08 Sana Biotechnology, Inc. Hypoimmunogene nervenzellen zur behandlung von neurologischen erkrankungen und zuständen
WO2021224395A1 (en) 2020-05-06 2021-11-11 Cellectis S.A. Methods for targeted insertion of exogenous sequences in cellular genomes
JP7891314B2 (ja) 2020-05-06 2026-07-16 セレクティス ソシエテ アノニム 治療用タンパク質の送達のために細胞を遺伝子改変する方法
KR20230022868A (ko) 2020-05-13 2023-02-16 주노 쎄러퓨티크스 인코퍼레이티드 재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법
US20230190871A1 (en) 2020-05-20 2023-06-22 Sana Biotechnology, Inc. Methods and compositions for treatment of viral infections
WO2021247836A1 (en) 2020-06-03 2021-12-09 Board Of Regents, The University Of Texas System Methods for targeting shp-2 to overcome resistance
AU2021286555B2 (en) 2020-06-09 2025-04-03 Cold Spring Harbor Laboratory Heterozygous CENH3 monocots and methods of use thereof for haploid induction and simultaneous genome editing
KR20230040337A (ko) 2020-06-19 2023-03-22 페이트 세러퓨틱스, 인코포레이티드 면역요법 사용을 위한 iPSC-유래 이펙터 세포 유형들의 조합
EP4171616A1 (de) 2020-06-26 2023-05-03 Juno Therapeutics GmbH Manipulierte t-zellen zur bedingten expression eines rekombinanten rezeptors, zugehörige polynukleotide und verfahren
KR20230051172A (ko) 2020-07-16 2023-04-17 아퀴타스 테라퓨틱스 인크. 지질 나노 입자에 사용하기 위한 양이온성 지질
AU2021325941A1 (en) 2020-08-13 2023-03-09 Sana Biotechnology, Inc. Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions
EP4501951A3 (de) 2020-08-25 2025-04-30 Kite Pharma, Inc. T-zellen mit verbesserter funktionalität
WO2022047424A1 (en) 2020-08-31 2022-03-03 Yale University Compositions and methods for delivery of nucleic acids to cells
KR20230074515A (ko) 2020-09-23 2023-05-30 크리스퍼 테라퓨틱스 아게 개선된 기능성 및 지속성을 갖는 붕괴된 레그나제-1 및/또는 tgfbrii를 지니는 유전자 조작된 t 세포
JP2023542705A (ja) 2020-09-25 2023-10-11 サンガモ セラピューティクス， インコーポレイテッド 核酸塩基編集のためのジンクフィンガー融合タンパク質
JP2023549780A (ja) 2020-11-04 2023-11-29 ジュノー セラピューティクス インコーポレイテッド 改変されたインバリアントｃｄ３免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法
US20240000051A1 (en) 2020-11-16 2024-01-04 Pig Improvement Company Uk Limited Influenza a-resistant animals having edited anp32 genes
IL303269A (en) 2020-12-03 2023-07-01 Century Therapeutics Inc Genetically engineered cells and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
WO2022137181A1 (en) 2020-12-23 2022-06-30 Crispr Therapeutics Ag Co-use of lenalidomide with car-t cells
US11965022B2 (en) 2020-12-31 2024-04-23 Sana Biotechnology, Inc. Methods and compositions for modulating CAR-T activity
CN117321197A (zh) 2021-01-12 2023-12-29 马奇疗法公司 背景依赖性、双链dna特异性脱氨酶及其用途
WO2022170117A1 (en) * 2021-02-04 2022-08-11 New York University Seamless integration of engineered zinc fingers into endogenous transcription factors to commandeer their natural functions
EP4305153A1 (de) 2021-03-09 2024-01-17 CRISPR Therapeutics AG Genetisch veränderte t-zellen mit ptpn2-knockout mit verbesserter funktionalität und antitumoraktivität
WO2022204071A1 (en) 2021-03-22 2022-09-29 Juno Therapeutics, Inc. Method to assess potency of viral vector particles
AU2022252997A1 (en) 2021-04-07 2023-09-28 Century Therapeutics, Inc. Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells
CA3214473A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells
AU2022253223A1 (en) 2021-04-07 2023-09-28 Century Therapeutics, Inc. Combined artificial cell death/reporter system polypeptide for chimeric antigen receptor cell and uses thereof
KR20240006059A (ko) 2021-05-05 2024-01-12 후지필름 셀룰러 다이내믹스, 인코포레이티드 Ipsc-유래된 미세아교세포에 대한 방법 및 조성물
WO2022251443A1 (en) 2021-05-26 2022-12-01 FUJIFILM Cellular Dynamics, Inc. Methods to prevent rapid silencing of genes in pluripotent stem cells
US20240226164A1 (en) 2021-05-27 2024-07-11 Sana Biotechnology, Inc. Hypoimmunogenic cells comprising engineered hla-e or hla-g
CN113429487B (zh) * 2021-06-21 2022-04-22 山东大学 一种能在水环境中去除抗生素耐药基因的人工合成蛋白
CA3225283A1 (en) 2021-07-14 2023-01-19 Sonja SCHREPFER Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
AU2022318664A1 (en) 2021-07-30 2024-02-29 Tune Therapeutics, Inc. Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
US20240254483A1 (en) 2021-07-30 2024-08-01 Tune Therapeutics, Inc. Compositions and methods for modulating expression of frataxin (fxn)
AU2022325231A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
US20260053851A1 (en) 2021-08-11 2026-02-26 Sana Biotechnology, Inc. Inducible systems for altering gene expression in hypoimmunogenic cells
CA3227108A1 (en) 2021-08-11 2023-02-16 Xiaomeng HU Genetically modified primary cells for allogeneic cell therapy
AU2022326565A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy
AU2022325955A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
KR20240055838A (ko) 2021-09-10 2024-04-29 후지필름 셀룰러 다이내믹스, 인코포레이티드 유도된 만능 줄기 세포 유래된 세포의 조성물 및 이의 사용 방법
US20230128917A1 (en) 2021-09-14 2023-04-27 Crispr Therapeutics Ag Genetically engineered immune cells having a disrupted cd83 gene
WO2023070043A1 (en) 2021-10-20 2023-04-27 Yale University Compositions and methods for targeted editing and evolution of repetitive genetic elements
JP2024540987A (ja) 2021-10-21 2024-11-06 バーテックス ファーマシューティカルズ インコーポレイテッド 低免疫細胞
US20250313861A1 (en) 2021-10-22 2025-10-09 Sana Biotechnology, Inc. Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
US20240409934A1 (en) 2021-10-25 2024-12-12 Board Of Regents, The University Of Texas System Foxo1-targeted therapy for the treatment of cancer
AU2022376962A1 (en) 2021-10-29 2024-04-18 FUJIFILM Cellular Dynamics, Inc. Dopaminergic neurons comprising mutations and methods of use thereof
US20250043269A1 (en) 2021-11-03 2025-02-06 The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad Precise Genome Editing Using Retrons
WO2023081900A1 (en) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
US20250064032A1 (en) 2021-12-10 2025-02-27 Pig Improvement Company Uk Limited Editing tmprss2/4 for disease resistance in livestock
WO2023111913A1 (en) 2021-12-15 2023-06-22 Crispr Therapeutics Ag Engineered anti-liv1 cell with regnase-1 and/or tgfbrii disruption
WO2023114943A2 (en) 2021-12-16 2023-06-22 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
US20230346836A1 (en) 2021-12-22 2023-11-02 Crispr Therapeutics Ag Genetically engineered t cells with disrupted casitas b-lineage lymphoma proto-oncogene-b (cblb) and uses thereof
EP4453202A1 (de) 2021-12-22 2024-10-30 Sangamo Therapeutics, Inc. Neue zinkfingerfusionsproteine zur nukleobaseneditierung
WO2023122337A1 (en) 2021-12-23 2023-06-29 Sana Biotechnology, Inc. Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
WO2023129937A1 (en) 2021-12-29 2023-07-06 Century Therapeutics, Inc. Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof
WO2023131616A1 (en) 2022-01-05 2023-07-13 Vib Vzw Means and methods to increase abiotic stress tolerance in plants
WO2023131637A1 (en) 2022-01-06 2023-07-13 Vib Vzw Improved silage grasses
US20250134999A1 (en) 2022-01-14 2025-05-01 Tune Therapeutics, Inc. Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
EP4463549A2 (de) 2022-01-14 2024-11-20 Tune Therapeutics, Inc. Zusammensetzungen, systeme und verfahren zur programmierung von t-zell-phänotypen durch gezielte genunterdrückung
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2023144199A1 (en) 2022-01-26 2023-08-03 Vib Vzw Plants having reduced levels of bitter taste metabolites
EP4479084A1 (de) 2022-02-14 2024-12-25 Sana Biotechnology, Inc. Verfahren zur behandlung von patienten mit einer vorherigen fehlgeschlagenen therapie mit hypoimmunogenen zellen
WO2023158836A1 (en) 2022-02-17 2023-08-24 Sana Biotechnology, Inc. Engineered cd47 proteins and uses thereof
TW202340457A (zh) 2022-02-28 2023-10-16 美商凱特製藥公司 同種異體治療細胞
WO2023166425A1 (en) 2022-03-01 2023-09-07 Crispr Therapeutics Ag Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
WO2023173123A1 (en) 2022-03-11 2023-09-14 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
US20230293646A1 (en) 2022-03-21 2023-09-21 Crispr Therapeutics Ag Methods and compositions for treating lipoprotein-related diseases
US20230331841A1 (en) 2022-03-23 2023-10-19 Crispr Therapeutics Ag Anti-cd83 car-t cells with regnase-1 and/or tgfbrii disruption
WO2023180968A1 (en) 2022-03-23 2023-09-28 Crispr Therapeutics Ag Anti-cd19 car-t cells with multiple gene edits and therapeutic uses thereof
WO2023192872A1 (en) 2022-03-28 2023-10-05 Massachusetts Institute Of Technology Rna scaffolded wireframe origami and methods thereof
KR20250004622A (ko) 2022-04-08 2025-01-08 페이트 세러퓨틱스, 인코포레이티드 종양 표적화를 위한 키메라 항원 수용체
KR20250005097A (ko) 2022-04-08 2025-01-09 페이트 세러퓨틱스, 인코포레이티드 고형 종양 표적화 골격을 갖는 세포 및 이의 용도
EP4532527A1 (de) 2022-05-27 2025-04-09 The Broad Institute, Inc. Verbesserte editoren für mitochondriale basen und verfahren zur bearbeitung mitochondrialer dna
US20250090582A1 (en) 2022-06-08 2025-03-20 Century Therapeutics, Inc. Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof
EP4536814A1 (de) 2022-06-08 2025-04-16 Century Therapeutics, Inc. Immuneffektorzellen aus induzierten pluripotenten stammzellen, die genetisch mit membrangebundenem il12 manipuliert wurden, und verwendungen davon
CN119630695A (zh) 2022-06-08 2025-03-14 世纪治疗股份有限公司 表达cd16变体和nkg2d的遗传工程化细胞及其用途
CN119522284A (zh) 2022-06-17 2025-02-25 克里斯珀医疗股份公司 基于脂质纳米颗粒(lnp)的眼部递送
WO2023248145A1 (en) 2022-06-21 2023-12-28 Crispr Therapeutics Ag Compositions and methods for treating human immunodeficiency virus
WO2023248147A1 (en) 2022-06-21 2023-12-28 Crispr Therapeutics Ag Methods and compositions for in vivo editing of stem cells
CA3260237A1 (en) 2022-06-24 2023-12-28 Tune Therapeutics, Inc. Compositions, systems and methods for reducing low-density lipoprotein by targeted gene repression
CN119451992A (zh) 2022-06-29 2025-02-14 克里斯珀医疗股份公司 靶向gpc-3的嵌合抗原受体和表达其的免疫细胞用于治疗用途
US20240003871A1 (en) 2022-06-29 2024-01-04 FUJIFILM Cellular Dynamics, Inc. Ipsc-derived astrocytes and methods of use thereof
EP4554967A2 (de) 2022-07-12 2025-05-21 Tune Therapeutics, Inc. Zusammensetzungen, systeme und verfahren zur gezielten transkriptionsaktivierung
WO2024013514A2 (en) 2022-07-15 2024-01-18 Pig Improvement Company Uk Limited Gene edited livestock animals having coronavirus resistance
JP2025523965A (ja) 2022-07-22 2025-07-25 ザ・ジョンズ・ホプキンス・ユニバーシティー デンドリマーが可能にする標的化細胞内ｃｒｉｓｐｒ／ｃａｓシステム送達および遺伝子編集
WO2024023802A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing-2 (tap-2) gene
WO2024023801A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing-1 (tap-1) gene
WO2024023804A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing binding protein (tapbp) gene
WO2024040254A2 (en) 2022-08-19 2024-02-22 Tune Therapeutics, Inc. Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
AU2023329392A1 (en) 2022-08-25 2025-02-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
JP2025531268A (ja) 2022-09-19 2025-09-19 チューン セラピューティクス インコーポレイテッド Ｔ細胞機能を調節するための組成物、システム、および方法
WO2024062388A2 (en) 2022-09-20 2024-03-28 Crispr Therapeutics Ag Genetically engineered immune cells expressing chimeric antigen receptor targeting cd20
JP2025536260A (ja) 2022-10-11 2025-11-05 イェール ユニバーシティー 細胞透過性抗体の組成物および使用方法
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
WO2024102838A1 (en) 2022-11-09 2024-05-16 Century Therapeutics, Inc. Engineered interleukin-7 receptors and uses thereof
CN120435498A (zh) 2022-11-10 2025-08-05 世纪治疗股份有限公司 具有抗-nectin4嵌合抗原受体的基因工程化细胞及其用途
CN120641131A (zh) 2022-12-01 2025-09-12 耶鲁大学 用于细胞内有效载荷递送的刺激反应性无痕工程化平台
US20240269189A1 (en) 2022-12-19 2024-08-15 FUJIFILM Holdings America Corporation Extracellular vesicle-enriched secretome composition derived from induced pluripotent stem cell derived-microglia and methods of use thereof
JP2026500040A (ja) 2022-12-23 2026-01-05 エピジェニック セラピューティクス プライベート リミテッド 複合体及びその使用
KR20250128349A (ko) 2022-12-23 2025-08-27 에피제닉 테라퓨틱스 피티이 리미티드 융합체 및 이의 용도
WO2024151541A1 (en) 2023-01-09 2024-07-18 Sana Biotechnology, Inc. Type-1 diabetes autoimmune mouse
WO2024163678A2 (en) 2023-02-01 2024-08-08 Tune Therapeutics, Inc. Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
WO2024163683A2 (en) 2023-02-01 2024-08-08 Tune Therapeutics, Inc. Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
US20260232729A1 (en) 2023-02-03 2026-08-13 C3S2 Gmbh Methods for non-viral manufacturing of engineered immune cells
US20260232844A1 (en) 2023-02-15 2026-08-13 Arbor Biotechnologies, Inc. Gene editing method for inhibiting aberrant splicing in stathmin 2 (stmn2) transcript
WO2024192108A1 (en) 2023-03-14 2024-09-19 Evolveimmune Therapeutics, Inc. Genetically modified car t cells and methods of making and using the same
AU2024257643A1 (en) 2023-04-21 2025-10-16 Kite Pharma, Inc. Allogenic therapeutic cells with reduced risk of immune rejection
CN121843705A (zh) 2023-05-03 2026-04-10 萨那生物科技公司 工程化胰岛细胞的给药和施用方法
WO2024243236A2 (en) 2023-05-22 2024-11-28 Sana Biotechnology, Inc. Methods of delivery of islet cells and related methods
TW202515898A (zh) 2023-06-30 2025-04-16 日商武田藥品工業股份有限公司 Ｈｔｔ抑制物及其用途
WO2025019742A1 (en) 2023-07-19 2025-01-23 Omega Therapeutics, Inc. Methods and compositions for modulating ctnnb1 expression
WO2025022290A1 (en) 2023-07-21 2025-01-30 Crispr Therapeutics Ag Modulating expression of alas1 (5'-aminolevulinate synthase 1) gene
CN121909284A (zh) 2023-07-31 2026-04-21 图恩疗法股份有限公司 用于调节il-2基因表达的组合物和方法
EP4754248A1 (de) 2023-07-31 2026-06-10 Tune Therapeutics, Inc. Zusammensetzungen und verfahren zur multiplex-aktivierung und -repression der t-zell-genexpression
WO2025038494A1 (en) 2023-08-11 2025-02-20 Tune Therapeutics, Inc. Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation
EP4771154A2 (de) 2023-09-01 2026-07-08 Renagade Therapeutics Management Inc. Geneditierungssysteme, zusammensetzungen und verfahren zur behandlung des vexas-syndroms
WO2025059073A1 (en) 2023-09-11 2025-03-20 Tune Therapeutics, Inc. Epigenetic editing methods and systems for differentiating stem cells
WO2025101938A2 (en) 2023-11-10 2025-05-15 Century Therapeutics, Inc. Genetically engineered cells having multi-transmembrane domain chimeric antigen receptors utilizing g protein-coupled receptor scaffolds, and uses thereof
WO2025106626A1 (en) 2023-11-15 2025-05-22 Century Therapeutics, Inc. Genetically engineered cells expressing c-x-c chemokine receptor type 4, and uses thereof
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025186726A1 (en) 2024-03-05 2025-09-12 Crispr Therapeutics Ag Modulating expression of agt (angiotensinogen) gene
WO2025207798A1 (en) 2024-03-26 2025-10-02 Century Therapeutics, Inc. Genetically engineered cells having anti-cd123 chimeric antigen receptors, and uses thereof
WO2025207795A1 (en) 2024-03-26 2025-10-02 Juno Therapeutics, Inc. Genetically engineered cells having anti-cd33 / anti-cd123 chimeric antigen receptors, and uses thereof
WO2025226122A1 (ko) * 2024-04-25 2025-10-30 (주)셀트리온 글루타민 합성효소 유전자를 불활성화시키는 방법 및 이를 이용한 목적 단백질의 생산 방법
WO2025224715A1 (en) 2024-04-26 2025-10-30 King Abdullah Univeristy Of Science And Technology Methods for improving precise genome modification and reducing unwanted mutations by crispr-cas editing
US20250345431A1 (en) 2024-05-10 2025-11-13 Juno Therapeutics, Inc. Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy
WO2025260068A1 (en) 2024-06-14 2025-12-18 Tune Therapeutics, Inc. Lipid nanoparticle formulation for delivery of nucleic acids to cells
WO2026006832A1 (en) 2024-06-28 2026-01-02 University Of Connecticut Gene modulation for treating cancer
WO2026015647A1 (en) 2024-07-09 2026-01-15 Tune Therapeutics, Inc. Compositions, systems, and methods for cell differentiation using targeted gene activation of dll4 and/or vcam1
WO2026064753A1 (en) 2024-09-23 2026-03-26 Tune Therapeutics, Inc. Dna methyltransferase-like protein (dnmt3l) or dna methyltransferase 3a (dnmt3a) repressor systems for epigenetic editing
WO2026122879A1 (en) 2024-12-05 2026-06-11 Massachusetts Institute Of Technology Compositions and methods for producing endotoxin-free phage
WO2026123001A2 (en) 2024-12-06 2026-06-11 Umoja Biopharma, Inc. Lineage-loci engineered cell therapy and related methods of producing and using same
WO2026128588A1 (en) 2024-12-10 2026-06-18 Yale University Compositions and methods for treating fibrosis
WO2026136848A2 (en) 2024-12-20 2026-06-25 Juno Therapeutics, Inc. Cd70-targeted cars and engineered cells comprising same and related methods
WO2026161895A1 (en) 2025-01-27 2026-07-30 Tune Therapeutics, Inc. Compositions, systems, and methods for epigenetic regulation of lipoprotein a (lpa) gene expression

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5317090A (en) * 1987-12-16 1994-05-31 Institut Pasteur Steroid/thyroid hormone receptor-related gene, which is inappropriately expressed in human hepatocellular carcinoma, and which is a retinoic acid receptor
US5340739A (en) * 1988-07-13 1994-08-23 Brigham & Women's Hospital Hematopoietic cell specific transcriptional regulatory elements of serglycin and uses thereof
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5096815A (en) * 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US4990607A (en) * 1989-03-14 1991-02-05 The Rockefeller University Alteration of gene expression in plants
EP0463081B1 (de) * 1989-03-17 1998-05-20 The Salk Institute For Biological Studies Zusammensetzung und testverfahren eines elementes als antwort auf ein hormon
JP3393867B2 (ja) * 1989-11-13 2003-04-07 マサチユーセツツ・インステイテユート・オブ・テクノロジー ウィルムス腫瘍遺伝子の位置決定と特徴付け
US5726288A (en) * 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
JPH06503642A (ja) * 1990-09-21 1994-04-21 ザ　ソーク　インスティテュート　フォア　バイオロジカル　スタディーズ プロトオンコタンパク質ｃ−ＪＵＮとホルモン受容体との間の機能的拮抗作用
US5324818A (en) * 1991-08-21 1994-06-28 The Regents Of The University Of Michigan Proteins useful in the regulation of κB-containing genes
US5243041A (en) * 1991-08-22 1993-09-07 Fernandez Pol Jose A DNA vector with isolated CDNA gene encoding metallopanstimulin
US5324638A (en) * 1992-05-13 1994-06-28 Sloan-Kettering Institute For Cancer Research Brain transcription factor, nucleic acids encoding same and uses thereof
JP4012243B2 (ja) * 1994-01-18 2007-11-21 ザ スクリップス リサーチ インスティチュート 亜鉛フィンガータンパク質誘導体およびそのための方法
US6242568B1 (en) 1994-01-18 2001-06-05 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
CA2196419C (en) * 1994-08-20 2007-08-21 Yen Choo Improvements in or relating to binding proteins for recognition of dna
US5789538A (en) * 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
US5972664A (en) * 1997-04-11 1999-10-26 Abbott Laboratories Methods and compositions for synthesis of long chain poly-unsaturated fatty acids
EP0905237A3 (de) * 1997-08-25 1999-12-22 Smithkline Beecham Corporation PIGR-2 ein Mitglied der Immunglobulingen-Superfamilie
US6140081A (en) * 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins

Also Published As

Publication number Publication date
EP1715040A2 (de) 2006-10-25
IL142440A0 (en) 2002-03-10
CN1330713A (zh) 2002-01-09
KR100659922B1 (ko) 2006-12-21
US7101972B2 (en) 2006-09-05
AU1037600A (en) 2000-05-08
JP2010143936A (ja) 2010-07-01
NZ511523A (en) 2004-01-30
US20100041028A1 (en) 2010-02-18
JP2002527097A (ja) 2002-08-27
NZ529584A (en) 2005-07-29
EP1121381B1 (de) 2006-04-19
EP1121381A2 (de) 2001-08-08
NZ529583A (en) 2005-07-29
CA2347025A1 (en) 2000-04-27
CA2347025C (en) 2012-01-03
ES2263290T3 (es) 2006-12-01
AU765630B2 (en) 2003-09-25
US7329541B2 (en) 2008-02-12
WO2000023464A2 (en) 2000-04-27
NZ529585A (en) 2005-07-29
ZA200102908B (en) 2002-06-26
US6610512B1 (en) 2003-08-26
DK1121381T3 (da) 2006-08-21
EP1715040B1 (de) 2011-05-11
US20050148075A1 (en) 2005-07-07
MXPA01003755A (es) 2010-09-07
CN1896099A (zh) 2007-01-17
BR9914599A (pt) 2001-11-13
CN1269958C (zh) 2006-08-16
US20060223757A1 (en) 2006-10-05
WO2000023464A3 (en) 2000-11-16
US6140081A (en) 2000-10-31
ATE509101T1 (de) 2011-05-15
IL142440A (en) 2010-06-16
EP1715040A3 (de) 2007-09-12
DE69930950T2 (de) 2006-12-14
DE69930950D1 (de) 2006-05-24
KR20010080189A (ko) 2001-08-22
IL199916A (en) 2011-06-30

Similar Documents

Publication Publication Date Title
DE69930950D1 (de) Zinkfinger-bindungsdomänen für gnn
IL143747A0 (en) Substituted aryl or heteroarylamides having retinoid-like biological activity
PT842934E (pt) Agonistas de 5-ht1f
TR200101815T2 (tr) Sulu reaktif dolgu bileşimleri (I).
CY1111126T1 (el) Σκευασμα οφθαλμικων σταγονων που περιεχει κετοτιφαινη
ATE490311T1 (de) Mutanten der alpha-amylase
BR9915515B1 (pt) composiÇço curÁvel de multicomponentes.
DE69813898D1 (de) Substituierte porphyrinen
PT1149092E (pt) 4- e 5-alciniloxindois e 4- e 5-alceniloxindois
DE69732309D1 (de) Primerzusammensetzungen für den Dentalbereich
ATE268750T1 (de) Proteintyrosinphosphatase inhibitoren
BR9907304B1 (pt) refratÁrio de alumina-magnÉsia-grafita.
TR200101756T2 (tr) Protein kinaz inhibitörleri olarak 4,5-pirazinoksindoller.
DE69913965D1 (de) Zusammensetzung basierend auf wasserdispergierbaren polyurethanen
ATE441712T1 (de) Die nukleotidsequenz ann bindende zink-finger domänen
ATE117343T1 (de) Pigmentierte antikorrosive zusammensetzung zur beschichtung.
BR9711273A (pt) 1,2,3,4- Tetraidro-2-dibenzofuranaminas substituidas e 2- aminociclohepta b benzofuranos
IL135634A0 (en) 5-htif agonists
ATE364616T1 (de) Nucleinsäuremolekül, kit und verwendung
ATE230033T1 (de) Verwendung von primern für universelle fingerprint-analysen
FR2787340B3 (fr) Boitier pour des automates de jeu ou similaires
NO20003938L (no) Vann-dispergerbare flaksammensetninger
GR980100275A (el) Λιποφιλες σπειρανικες, 4,6-διαμινο-συμμετρικες τριαζινες και τα αντιστοιχα αλατα, τα ισομερη, στερεομερη και εναντιομερη τους, αναστολεις του ενζυμου της διυδροφολικης αναγωγασης

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1121381

Country of ref document: EP